Clinical Trial

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

Study acronym: SOUNDTRACK-B
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2027-11-24 -> 2028-04-21 2026-08-14
notable Enrollment increased: 240 -> 270 participants 2026-06-26
notable Primary completion pushed: 2027-03-10 -> 2027-11-24 2026-06-26
minor Completion pushed: 2029-06-14 -> 2032-10-21 2026-06-26
Trial Details
NCT Number NCT06526793
Lead Sponsor AstraZeneca
Conditions B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
Enrollment 270 participants
Start Date 2024-11-27
Primary Completion 2028-04-21 (estimated)
Study Completion 2032-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-08-13